Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dd30318144472d1577cc38180d6eec83 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e1fd0148f9263372f4d57bc0d1217ba2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4bb0d3339cfbd539efc4b01b186339e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1efca4e202939064a98613acb2137dbb http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96840501e6a5e923cfcb5c91ea840d90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db64b115efb15f24f690bd82c9e3331a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9af21254b7bbd6b91be078c8d4d2849b |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L1-305 |
filingDate |
2004-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c39a5a6ba436142a9ff836a2b2500b2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1cf9e1839f19d3cbc31f9a2f8dc7b5f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b139fec27926fdc13405f722c16f692d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa2cee81c6edd11f6811f18033ea31c5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b0bebb6f71e1add71aad92d896e67de http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbdc4df676c17b4b0bec82e6e9820777 |
publicationDate |
2004-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2004087199-A1 |
titleOfInvention |
Composition for improving insulin resistance |
abstract |
It is intended to provide a composition for improving insulin resistance which contains β-conglycinin as the active ingredient. This composition can lower insulin resistance and thus prevent arteriosclerosis or type II diabetes without any side effects or contraindications as observed in the existing drugs. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011122389-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007023776-A1 |
priorityDate |
2003-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |